Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.49 |
| ▸ | PRCP | P42785 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15554269 | 0.89 | CYP2D6 (0.70) | CYP2D6KMT2APTGS2 | |
| SCHEMBL3392489 | 0.89 | CYP2D6 (0.70) | CYP2D6KMT2APTGS2 | |
| SCHEMBL6393928 | 0.84 | CYP2D6 (0.57) | CYP2D6KMT2ACNR1PTGS2IDO1 | |
| SCHEMBL28329595 | 0.84 | CYP2D6 (0.57) | CYP2D6KMT2AMEN1CNR1PTGS2 | |
| SCHEMBL15553593 | 0.83 | CYP2D6 (0.52) | CYP2D6KMT2AMEN1PTGS2GPR139 | |
| SCHEMBL6180012 | 0.82 | CYP2D6 (0.55) | CYP2D6KMT2APTGS2CES2CES1 | |
| SCHEMBL11350641 | 0.81 | SLC6A2 (0.48) | CYP2D6FFAR2KMT2AMEN1POLB | |
| SCHEMBL1677207 | 0.81 | FFAR2 (0.65) | FFAR2KMT2AMEN1 | |
| SCHEMBL1405698 | 0.81 | FFAR2 (0.65) | FFAR2KMT2AMEN1 | |
| SCHEMBL68169 | 0.81 | FFAR2 (0.65) | FFAR2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569013-B2 | Penicillin-G acylases | CODEXIS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120270282-A1 | PENICILLIN-G ACYLASES | CODEXIS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8247192-B2 | Penicillin-G acylases | CODEXIS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20100143968-A1 | PENICILLIN-G ACYLASES | CODEXIS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270282-A1 | PENICILLIN-G ACYLASES | PGLS, PNP, NAAA | CYP2D6 1443/4885FFAR2 3950/4885PRCP 416/4885 |
| US-20100143968-A1 | PENICILLIN-G ACYLASES | PGLS, PNP, NAAA | CYP2D6 1443/4885FFAR2 3950/4885PRCP 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.